Microfluidic Production and Application of Lipid Nanoparticles for Nucleic Acid Transfection


Authors: A. Thomas, S.M. Garg, R.A.G. De Souza, E. Ouellet, G. Tharmarajah, D. Reichert, M. Ordobadi, S. Ip and E.C. Ramsay

Journal: Multiple Myeloma

DOI: 10.1007/978-1-4939-7865-6_14

Publication - Abstract

May 25, 2018

siRNA microRNA DNA

Abstract

Lipid nanoparticles (LNPs) are established in the biopharmaceutical industry for efficient encapsulation and cytosolic delivery of nucleic acids for potential therapeutics, with several formulations in clinical trials. The advantages of LNPs can also be applied in basic research and discovery with a microfluidic method of preparation now commercially available that allows preparations to be scaled down to quantities appropriate for cell culture. These preparations conserve expensive nucleic acids while maintaining the particle characteristics that have made LNPs successful in later stages of genetic medicine development. Additionally, this method and the resulting LNPs are seamlessly scalable to quantities appropriate for in vivo models and development of nucleic acid therapeutics.The present work describes the methodology for preparing LNPs loaded with siRNA, mRNA or plasmids using a commercially available microfluidic instrument and an accompanying transfection kit. Guidelines for application to cultured cells in a well-plate format are also provided.

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Apr 01, 2017
 Biochimica et Biophysica Acta

Neurotoxic Mechanisms by which the USP14 Inhibitor IU1 Depletes Ubiquitinated Proteins and Tau in Rat Cerebral Cortical Neurons: Relevance to Alzheimer's Disease

M.J. Kiprowska, A. Stepanova, D.R. Todaro, A. Galkin, A. Haasd, S.M. Wilson and M.E. Figueiredo-Pereira

Neuroscience siRNA Nucleic Acid Lipid Nanoparticles

In Alzheimer's disease proteasome activity is reportedly downregulated, thus increasing it could be therapeutically beneficial. The proteasome-associated deubiquitinase USP14 disassembles polyubiquitin-chains, potentially delaying proteasome-depend...

Read More


Publication - Abstract

Mar 16, 2019
Pharmaceutics

What Drives Innovation: The Canadian Touch on Liposomal Therapeutics

A.W.Y. Leung, C. Amador, L.C. Wang, U.V. Mody and M.B. Bally

siRNA Nucleic Acid Lipid Nanoparticles Liposomes
Liposomes are considered one of the most successful drug delivery systems (DDS) given their established utility and success in the clinic. In the past 40–50 years, Canadian scientists have made ground-breaking discoveries, many of which were successfully translated to the c...
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up